Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients : A randomized clinical trial
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC..
BACKGROUND: Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. A considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule.
METHODS: In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the difference in the rate of a positive antibody response (SARS-CoV-2 IgG ≥10 AU/ml) between one and two booster doses at 1 month after the final booster dose.
RESULTS: A positive humoral response was observed in 36 (62%) patients receiving two booster doses and in 28 (44%) patients receiving one booster dose (odds ratio [OR], 2.10, 95% confidence interval [CI], 1.02-4.34, p = .043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p = .009). The number of patients with positive virus neutralizing antibody (VNA) levels was numerically higher with two booster doses compared to one booster dose, but without statistical significance (66% vs. 50%, p = .084). There was no significant difference in positive seroconversions rate and antibody levels between mRNA-1273 and BNT162b2.
CONCLUSION: A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 25(2023), 5 vom: 19. Okt., Seite e14150 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Drenko, Petr [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/tid.14150 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM362215758 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM362215758 | ||
003 | DE-627 | ||
005 | 20231226090757.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/tid.14150 |2 doi | |
028 | 5 | 2 | |a pubmed24n1207.xml |
035 | |a (DE-627)NLM362215758 | ||
035 | |a (NLM)37724748 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Drenko, Petr |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients |b A randomized clinical trial |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.10.2023 | ||
500 | |a Date Revised 23.10.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC. | ||
520 | |a BACKGROUND: Kidney transplant recipients are at risk for a severe course of COVID-19 with a high mortality rate. A considerable number of patients remains without a satisfactory serological response after the baseline and adjuvant SARS-CoV-2 vaccination schedule | ||
520 | |a METHODS: In this prospective, randomized study, we evaluated the efficacy and safety of one and two booster doses of mRNA vaccines (either mRNA-1273 or BNT162b2) in 125 COVID-19 naive, adult kidney transplant recipients who showed an insufficient humoral response (SARS-CoV-2 IgG <10 AU/ml) to the previous 2-dose vaccination schedule. The primary outcome was the difference in the rate of a positive antibody response (SARS-CoV-2 IgG ≥10 AU/ml) between one and two booster doses at 1 month after the final booster dose | ||
520 | |a RESULTS: A positive humoral response was observed in 36 (62%) patients receiving two booster doses and in 28 (44%) patients receiving one booster dose (odds ratio [OR], 2.10, 95% confidence interval [CI], 1.02-4.34, p = .043). Moreover, median SARS-CoV-2 IgG levels were higher with two booster doses (p = .009). The number of patients with positive virus neutralizing antibody (VNA) levels was numerically higher with two booster doses compared to one booster dose, but without statistical significance (66% vs. 50%, p = .084). There was no significant difference in positive seroconversions rate and antibody levels between mRNA-1273 and BNT162b2 | ||
520 | |a CONCLUSION: A higher number of kidney transplant recipients achieved a positive antibody response after two booster doses compared to one booster dose | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 mRNA vaccine | |
650 | 4 | |a SARS-CoV-2 vaccination | |
650 | 4 | |a kidney transplantation | |
650 | 4 | |a randomized trial | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a BNT162 Vaccine |2 NLM | |
650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
650 | 7 | |a EPK39PL4R4 |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
650 | 7 | |a mRNA Vaccines |2 NLM | |
700 | 1 | |a Kacer, Martin |e verfasserin |4 aut | |
700 | 1 | |a Kielberger, Lukas |e verfasserin |4 aut | |
700 | 1 | |a Vlas, Tomas |e verfasserin |4 aut | |
700 | 1 | |a Topolcan, Ondrej |e verfasserin |4 aut | |
700 | 1 | |a Kucera, Radek |e verfasserin |4 aut | |
700 | 1 | |a Reischig, Tomas |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 25(2023), 5 vom: 19. Okt., Seite e14150 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2023 |g number:5 |g day:19 |g month:10 |g pages:e14150 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.14150 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 25 |j 2023 |e 5 |b 19 |c 10 |h e14150 |